Want to see GDRX full AI Analyst Report?
GDRX Stock Chart & Stats
$2.96
$0.09(3.04%)
At close: 4:00 PM EDT
$2.96
$0.09(3.04%)
Day’s Range― - ―
52-Week Range$1.77 - $5.81
Previous CloseN/A
Volume1.06M
Average Volume (3M)1.02M
Market Cap
$1.04B
Enterprise Value$1.25K
Total Cash (Recent Filing)$296.11M
Total Debt (Recent Filing)$538.95M
Price to Earnings (P/E)52.4
Beta0.92
Next Earnings
Nov 10, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding104,711,190
10 Day Avg. Volume911,183
30 Day Avg. Volume1,022,773
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside35.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.31
Revenue Forecast (FY)$789.27M
Bulls Say, Bears Say
Bulls Say
Cash GenerationGoodRx has sustained positive operating and free cash flow even when reported earnings were weak, indicating durable cash conversion. This recurring cash generation funds reinvestment into Pharma Direct and subscriptions, reduces reliance on external financing, and underpins multi‑quarter strategic execution.
Pharma Direct Growth & GuidanceRapid Pharma Direct expansion meaningfully diversifies revenue away from legacy prescription transactions. High growth and management's raised FY26 guidance reflect scalable commercial programs and direct contracts with major retailers, supporting a durable, higher-growth revenue vector over coming quarters.
Manageable LeverageDebt below equity and improving leverage trends provide financial flexibility to invest in strategic initiatives and absorb transaction headwinds. A healthier balance sheet supports capital allocation to subscriptions and e‑commerce, lowers refinancing risk, and preserves runway for multi‑period strategic shifts.
Bears Say
Sharp TTM Revenue DeclineA 33.7% TTM revenue contraction signals deep, persistent headwinds in core demand or monetization. Large top‑line erosion impairs operating leverage, forces heavier reliance on new initiatives to replace lost volume, and makes multi‑period profitability improvement harder to sustain absent durable revenue recovery.
Legacy Prescription Transactions WeaknessThe 24% YoY decline in prescription transactions—historically a primary revenue source—reduces high-margin transaction flows and raises unit economics pressure. Persistent PTR erosion forces accelerated migration to lower‑visibility revenue streams while increasing execution risk for long‑term margin recovery.
Limited Visibility & Competitive/regulatory RiskAbsence of a consolidated prescription volume metric constrains transparency into true user engagement and prescription routing trends. Coupled with rising competitive and regulatory headwinds in GLP‑1s, telehealth and payer markets, this limits predictability of long‑term revenue and unit‑economics evolution.
GoodRx Holdings News
GDRX FAQ
What was Goodrx Holdings, Inc.’s price range in the past 12 months?
Goodrx Holdings, Inc. lowest stock price was $1.77 and its highest was $5.81 in the past 12 months.
What is Goodrx Holdings, Inc.’s market cap?
Goodrx Holdings, Inc.’s market cap is $1.04B.
When is Goodrx Holdings, Inc.’s upcoming earnings report date?
Goodrx Holdings, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 95 days.
How were Goodrx Holdings, Inc.’s earnings last quarter?
Goodrx Holdings, Inc. released its earnings results on Aug 05, 2026. The company reported $0.08 earnings per share for the quarter, the consensus estimate of $0.08 by $0.
Is Goodrx Holdings, Inc. overvalued?
According to Wall Street analysts Goodrx Holdings, Inc.’s price is currently Undervalued.
Does Goodrx Holdings, Inc. pay dividends?
Goodrx Holdings, Inc. does not currently pay dividends.
What is Goodrx Holdings, Inc.’s EPS estimate?
Goodrx Holdings, Inc.’s EPS estimate is 0.08.
How many shares outstanding does Goodrx Holdings, Inc. have?
Goodrx Holdings, Inc. has 104,711,190 shares outstanding.
What happened to Goodrx Holdings, Inc.’s price movement after its last earnings report?
Goodrx Holdings, Inc. reported an EPS of $0.08 in its last earnings report, expectations of $0.08. Following the earnings report the stock price went up 13.761%.
Which hedge fund is a major shareholder of Goodrx Holdings, Inc.?
Currently, no hedge funds are holding shares in GDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GoodRx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (35.14% Upside)
$4.00 (35.14% Upside)
Blogger Sentiment
Bullish
GDRX Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 287.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.05%
Trailing 12-Months
Company Description
Goodrx Holdings, Inc.
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
GDRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced material near-term headwinds in the legacy prescription transactions business (PTR) — notably a 24% YoY decline in PTR revenue and persistent unit-economics pressure — against strong and accelerating growth in strategic areas (Pharma Direct up 82% YoY, subscriptions +16% YoY), improved operational scalability in e-commerce, and a raised full-year guidance. Management emphasized durable strategy execution, margin discipline (30% adjusted EBITDA margin in Q1), and momentum in Pharma Direct and condition-specific subscriptions. While legacy PTR trends and macro/regulatory uncertainty are notable risks, the company’s improved guidance, profitable quarter, and rapid Pharma Direct expansion weigh positively.View all GDRX earnings summariesGDRX Revenue Breakdown
73.41% Prescription transactions
12.58% Subscription
11.34% Pharma manufacturer solutions
2.67% Other
GDRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(35.14% Upside)
Technical Analysis
Ownership Overview
13.03% Insiders
10.09% Mutual Funds
5.32% Other Institutional Investors
62.80% Public Companies and
Individual Investors